Human Complement factor H ELISA kit

Name: Human Complement factor H ELISA kit
SKU: DEIA-XY2149
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

plasma, serum, urine, saliva, milk, CSF, cell culture samples

Species Reactivity

Human

Intended Use

The CD Human Complement Factor H ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of CFH in human plasma, serum, urine, saliva, milk, CSF, and cell culture samples.

Storage

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Diluent (1x) may be stored for up to 30 days at 2-8°C.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Precision

Sensitivity

The minimum detectable dose of human CFH as calculated by 2SD from the mean of a zero standard was established to be 0.25 ng/ml.

General Description

Complement factor H (CFH, H factor 1) is a 1213-residue plasma glycoprotein that regulates the function of the alternative complement pathway. The CFH gene encodes a 155-kDa protein containing 20 tandem complement control protein (CCP) modules, also known as short consensus repeats (about 60 amino acids each), and an alternative spliced 45-kDa protein. It binds to C3b to accelerate the decay of the C3 convertase C3bBb and also acts as a cofactor for complement factor I-mediated C3b cleavage. Human CFH is particularly important for selectively protecting self-surfaces by binding to glycosaminoglycans on host cells.

Citations

Have you cited DEIA-XY2149 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Antribacter gilvus gen. nov., sp. nov., a new member of the family Promicromonosporaceae from a karstic cavern

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY

Authors: Zhang, Ling-Yu; Fang, Bao-Zhu; Jiao, Jian-Yu; Zhang, Xiao-Tong; Liu, Lan; Meng, Xiao-Lin; Ming, Hong; Nie, Guo-Xing; Li, Wen-Jun

Abstract

A novel actinobacterium, designated strain CFH 30434(T), was isolated from a soil sample collected from a karst cave in Luoyang, Henan Province, PR China. The taxonomic position of the strain was investigated by using a polyphasic approach. Cells of the strain were aerobic, Gram-stain-positive, non-motile and coccoid or short rods. The strain was found to be oxidase-positive and weakly catalase-positive. Strain CFH 30434(T) grew optimally at 28 degrees C, pH 7.0-9.0 and in the presence of up to 0-1.5 % NaCl (w/v). The whole-cell sugars were glucose, mannose and rhamnose. The major isoprenoid quinone was MK-9(H-8) and the major fatty acids (>10 % of the total fatty acids compositions) were anteiso-C-15:0, iso-C-18:0 and iso-C-14:0 The polar lipids detected were diphosphatidylglycerol, phosphatidylinositol, phosphatidylinositol mannoside, an unidentified phosphoglycolipid, an unidentified phospholipid and an unidentified glycolipid. The genomic DNA G+C content was determined to be 72.3 mol%. The results of phylogenetic analysis of 16S rRNA gene sequences indicated that CFH 30434(T) clustered within the family Promicromonosporaceae, and closely with the type strains of Xylanimicrobium pachnodae DSM 12657(T), Myceligenerans crystallogenes DSM 17134(T)- and Promicromonospora xylanilytica CCTCC AA 208046(T) (97.3 %, 96.2 and 95.9 % sequence similarities, respectively). Phylogenetic analysis showed that strain CFH 30434(T) formed a separate evolutionary branch, and was parallel to other related genera of Promicromonosporaceae. Its phylogenetic distinctiveness and distinguishing phenotypic characteristics supported that strain CFH 30434(T) represents a novel genus of the family Promicromonosporaceae, for which the name Antribacter gilvus gen. nov., sp. nov. is proposed. The type strain is CFH 30434(T) (=CGMCC 1.13856(T) =KCTC 49093(T)).

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration

PHARMACEUTICALS

Authors: Shijo, Taiyo; Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Sugiyama, Atsushi; Matsubara, Mio; Fukuda, Yoshiko; Mabuchi, Fumihiko; Kashiwagi, Kenji

Abstract

We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (n = 129) and polypoidal choroidal vasculopathy (n = 132). A total of 261 patients were treated with as-needed intravitreal aflibercept injection (IAI) after three monthly IAIs and the completion of a one-year follow-up. One hundred and seventy-two healthy volunteers served as controls. Genotyping of ARMS2 A69S (rs10490924), CFH I62V (rs800292), SKIV2L-C2-CFB (rs429608), C3 (rs2241394), ADAMTS-9 (rs6795735) and CETP (rs3764261) was performed for all participants. A total of 63 PRSs were quantified. There was a positive association between the PRS involving ARMS2, CFH, C3, and ADAMTS-9 and best-corrected visual acuity at twelve months (p = 0.046, multiple regression analysis). When comparing PRSs of patients requiring retreatment and of patients without retreatment, 35 PRSs were significantly greater in patients requiring retreatment than in patients without requiring retreatment, with the PRS involving ARMS2 and CFH being most significantly associated (p = 1.6 x 10(-4)). The number of additional injections was significantly associated with 40 PRSs and the PRS involving ARMS2 and CFH showed a most significant p-value (p = 2.42 x 10(-6)). Constructing a PRS using a combination with high-risk variants might be informative for predicting the response to IAI for exudative AMD.